Published in Int J Hematol on November 29, 2008
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood (2011) 1.91
A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell (2013) 1.59
Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget (2011) 1.27
The CML stem cell: evolution of the progenitor. Cell Cycle (2009) 1.10
The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy. Cell Cycle (2014) 1.09
Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate. Haematologica (2010) 0.95
Retention of CD34+ CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR-ABL inhibitors. Leukemia (2012) 0.79
Prevalence of Abelson murine leukemia viral oncogene homolog-breakpoint cluster region fusions and correlation with peripheral blood parameters in chronic myelogenous leukemia patients in Lorestan Province, Iran. Int J Appl Basic Med Res (2016) 0.75
One more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a "hypoxic" environment. Hypoxia (Auckl) (2014) 0.75
Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism. Oncotarget (2016) 0.75
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med (2004) 11.29
Targeted cancer therapy. Nature (2004) 7.81
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2006) 6.89
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood (2002) 6.64
Dynamics of chronic myeloid leukaemia. Nature (2005) 6.63
Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell (2007) 3.59
Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci U S A (2002) 3.50
Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med (2006) 3.13
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A (2006) 2.94
Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer (2008) 2.41
Discontinuation of imatinib therapy after achieving a molecular response. Blood (2004) 2.23
Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol (1999) 1.58
Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia (2007) 1.58
How I treat chronic myeloid leukemia in the imatinib era. Blood (2007) 1.51
Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica (2005) 1.51
Heterogeneity of human peripheral blood eosinophil-type colonies: evidence for a common basophil-eosinophil progenitor. Blood (1985) 1.27
Identification of pure and mixed basophil colonies in culture of human peripheral blood and marrow cells. Blood (1984) 1.15
Optimizing therapy of chronic myeloid leukemia. Exp Hematol (2007) 0.99
The challenges of targeting chronic myeloid leukemia stem cells. Clin Lymphoma Myeloma (2007) 0.90
New strategies in chronic myeloid leukemia. Int J Hematol (2006) 0.87
Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia. Leukemia (2002) 0.87
Abnormalities in the erythroid progenitor compartments in patients with chronic myelogenous leukemia (CML). Exp Hematol (1979) 0.84
Differences between normal and CML stem cells: potential targets for clinical exploitation. Stem Cells (1998) 0.81
Stem cells in chronic myeloid leukaemia. Cancer Biomark (2007) 0.80
Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia. Tohoku J Exp Med (2006) 0.77
Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res (2006) 17.42
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
Stems cells and the pathways to aging and cancer. Cell (2008) 5.99
CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell (2009) 5.22
let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull (2006) 4.42
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2008) 4.26
Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A (2003) 4.09
Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol (2008) 3.12
Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol (2010) 2.64
Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci (2007) 2.61
Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol (2009) 2.52
Coordinated regulation of life and death by RB. Nat Rev Cancer (2003) 2.39
Cancer stem cells and self-renewal. Clin Cancer Res (2010) 2.37
MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep (2006) 2.29
Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res (2007) 2.25
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol (2005) 2.24
MicroRNA-143 and -145 in colon cancer. DNA Cell Biol (2007) 2.24
Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology (2009) 2.21
EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood (2011) 2.18
Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases. J Cell Sci (2003) 2.10
Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med (2012) 2.06
Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci U S A (2009) 2.02
Genetic variants in C5 and poor response to eculizumab. N Engl J Med (2014) 1.91
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood (2003) 1.87
Chronic myeloid leukemia stem cells. J Clin Oncol (2008) 1.82
Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol (2008) 1.81
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov (2013) 1.81
Integrin activation and matrix binding mediate cellular responses to mechanical stretch. J Biol Chem (2005) 1.80
Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood (2011) 1.79
Mutations of ARX are associated with striking pleiotropy and consistent genotype-phenotype correlation. Hum Mutat (2004) 1.76
Modulation of the F-actin cytoskeleton by c-Abl tyrosine kinase in cell spreading and neurite extension. J Cell Biol (2002) 1.72
Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell (2008) 1.71
Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol (2013) 1.70
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood (2005) 1.66
Nicorandil promotes myocardial capillary and arteriolar growth in the failing heart of Dahl salt-sensitive hypertensive rats. Hypertension (2005) 1.62
A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell (2013) 1.59
Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res (2010) 1.59
Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene (2002) 1.56
Targeting the RB-pathway in cancer therapy. Clin Cancer Res (2010) 1.54
Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int J Cancer (2006) 1.53
A myogenic differentiation checkpoint activated by genotoxic stress. Nat Genet (2002) 1.53
Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia. Cancer Sci (2012) 1.48
Double-strand DNA breaks recruit the centromeric histone CENP-A. Proc Natl Acad Sci U S A (2009) 1.47
Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci U S A (2003) 1.47
Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients. Cancer Sci (2010) 1.46
Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol Cell Biol (2006) 1.45
Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell (2012) 1.43
Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Mol Ther (2010) 1.43
Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer (2005) 1.42
MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett (2011) 1.42
Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett (2010) 1.42
Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: a multicenter validation study. Leuk Res (2012) 1.42
Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ J (2007) 1.41
Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J Exp Med (2003) 1.40
Postoperative hyperglycemia and atrial fibrillation after coronary artery bypass graft surgery. Circ J (2014) 1.39
BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci U S A (2008) 1.34
Characterized mechanism of alpha-mangostin-induced cell death: caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells. Bioorg Med Chem (2007) 1.33
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica (2011) 1.32
Arx homeobox gene is essential for development of mouse olfactory system. Development (2005) 1.31
A novel optical assay system for the quantitative measurement of chemotaxis. J Immunol Methods (2003) 1.30
Targeted disruption of mouse ortholog of the human MYH9 responsible for macrothrombocytopenia with different organ involvement: hematological, nephrological, and otological studies of heterozygous KO mice. Biochem Biophys Res Commun (2004) 1.27
c-Abl phosphorylates Dok1 to promote filopodia during cell spreading. J Cell Biol (2004) 1.26
ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. Proc Natl Acad Sci U S A (2012) 1.25
Selection of mammalian cells based on their cell-cycle phase using dielectrophoresis. Proc Natl Acad Sci U S A (2007) 1.23
Signal-dependent protection from apoptosis in mice expressing caspase-resistant Rb. Nat Cell Biol (2002) 1.22
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood (2009) 1.21
Selective elimination of leukemia stem cells: hitting a moving target. Cancer Lett (2012) 1.21
Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol (2007) 1.20
RB restricts DNA damage-initiated tumorigenesis through an LXCXE-dependent mechanism of transcriptional control. Mol Cell (2011) 1.16
Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. Int J Hematol (2013) 1.14
The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. J Exp Med (2013) 1.14
Induction of cell retraction by the combined actions of Abl-CrkII and Rho-ROCK1 signaling. J Cell Biol (2008) 1.13
BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol (2005) 1.13
Modulation of DNA damage-induced apoptosis by cell adhesion is independently mediated by p53 and c-Abl. Proc Natl Acad Sci U S A (2003) 1.12
Molecular evaluation of endothelial progenitor cells in patients with ischemic limbs: therapeutic effect by stem cell transplantation. Arterioscler Thromb Vasc Biol (2004) 1.12
Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. Biochem Biophys Res Commun (2009) 1.12